Catalyst Pharmaceuticals Inc

-0.01 (-0.26%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)402.14M
Current PE5.63
Forward PE 5.56
2yr Forward PE 10.24
See more stats
Estimates Current Quarter
Revenue$33.63 Million
Adjusted EPS$0.10
See more estimates
10-Day MA$4.06
50-Day MA$3.82
200-Day MA$3.83
See more pivots

Catalyst Pharmaceuticals, Inc. Stock, NASDAQ:CPRX

355 Alhambra Circle, Suite 1250, Coral Gables, Florida 33134
United States of America
Phone: +1.305.420.3200
Number of Employees: 76


Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.